Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
2.
Adv Neurobiol ; 24: 193-206, 2020.
Article in English | MEDLINE | ID: mdl-32006361

ABSTRACT

Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders with poorly understood etiology that are defined exclusively on the basis of behavioral observations. This disorder has been linked to increased levels of oxidative stress and lower antioxidant capacity. Oxidative stress in autism has been studied at the membrane level and also by measuring products of lipid peroxidation, detoxifying agents (such as glutathione), and antioxidants involved in the defense system against reactive oxygen species (ROS). Several studies have suggested alterations in the activities of antioxidant enzymes such as superoxide dismutase, glutathione peroxidase, and catalase in autism. Additionally, altered glutathione levels and homocysteine/methionine metabolism, increased inflammation, excitotoxicity, as well as mitochondrial and immune dysfunction have been suggested in autism. Moreover, environmental and genetic risk factors may intensify vulnerability to oxidative stress in autism. Collectively, these studies suggest increased oxidative stress in autism that may contribute to the development of this disease both in terms of pathogenesis and clinical symptoms. Antioxidant supplementation, or ways to improve the altered metabolite levels in the interconnected transmethylation and transsulfuration pathways, has been associated with decreased autistic behaviors and severity. This chapter provides a conceptual framework on oxidative stress and antioxidants utility. These types of interventions should be further studied in order to determine their effectiveness at improving metabolic imbalances.


Subject(s)
Antioxidants/metabolism , Autism Spectrum Disorder/metabolism , Oxidative Stress , Autism Spectrum Disorder/enzymology , Autistic Disorder/enzymology , Autistic Disorder/metabolism , Humans
3.
Adv Neurobiol ; 24: 573-586, 2020.
Article in English | MEDLINE | ID: mdl-32006374

ABSTRACT

Autism is a developmental disorder that affects communication and behavior. Although autism can be diagnosed at any age, it is said to be a "developmental disorder" because symptoms generally appear in the first 2 years of life. The primary cause of autism is still not clear and therapy is currently restricted to controlling behavioral abnormalities. However, emerging studies have shown a link between mitochondrial dysfunction and autism. Dietary supplements that promote mitochondrial biogenesis and inhibit the production of oxidative stress have been used to treat autism patients. Dietary adjustments in treating autism is a novel approach to suppress autistic symptoms. Supplementation with antioxidants has been found to not only inhibit cognitive decline but also improve behavioral symptoms in autism. Dietary supplements fortified with vitamins should only be given under the supervision of a physician. A wide range of nutraceuticals are under clinical trials to understand whether they physiologically target mitochondrial pathways and improve the quality of life in autism.


Subject(s)
Autistic Disorder/diet therapy , Diet Therapy , Dietary Proteins/therapeutic use , Autistic Disorder/metabolism , Autistic Disorder/pathology , Dietary Supplements , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondria/pathology , Oxidative Stress/drug effects , Quality of Life
4.
Adv Neurobiol ; 24: 601-614, 2020.
Article in English | MEDLINE | ID: mdl-32006376

ABSTRACT

Autism is a complex neurodevelopmental disorder that is evident in early childhood and can persist throughout the entire life. The disease is basically characterized by hurdles in social interaction where the individuals demonstrate repetitive and stereotyped interests or patterns of behavior. A wide number of neuroanatomical studies with autistic patients revealed alterations in brain development which lead to diverse cellular and anatomical processes including atypical neurogenesis, neuronal migration, maturation, differentiation, and degeneration. Special education programs, speech and language therapy, have been employed for the amelioration of behavioral deficits in autism. Although commonly prescribed antidepressants, antipsychotics, anticonvulsants, and stimulants have revealed satisfactory responses in autistic individuals, adverse side effects and increased risk of several other complications including obesity, dyslipidemia, diabetes mellitus, thyroid disorders, etc. have compelled the researchers to turn their attention toward herbal remedies. Alternative approaches with natural compounds are on continuous clinical trial to confirm their efficacy and to understand their potential in autism treatment. This chapter aims to cover the major plant-based natural products which hold promising outcomes in the field of reliable therapeutic interventions for autism.


Subject(s)
Autism Spectrum Disorder/drug therapy , Biological Products/therapeutic use , Herbal Medicine , Phytotherapy , Autistic Disorder/drug therapy , Humans
5.
Adv Neurobiol ; 24: 661-678, 2020.
Article in English | MEDLINE | ID: mdl-32006379

ABSTRACT

Autism spectrum disorder (ASD) is a developmental disorder that influences communication and behavior. Numerous researches propose that genes can act together with manipulations from the environment to affect development in ways that lead to ASD. The broad range of issues facing people with ASD means that there is no single proper drug and treatment for ASD. Numerous shortcomings associated with the present conventional therapeutic strategies have forced researchers to venture into alternative natural sources for effective compounds. The marine environment has emerged as an alternate search environment due to its versatile conditions where organisms employ various biodefense mechanisms for their survival. Ascidians are an excellent source for unique bioactive compounds with nutritive and therapeutic content and it still holds credit for being an underused source from marine animals. Bioactive compounds isolated from ascidians have various commendable biomedical applications due to their unique chemical structures. The present chapter will focus on the potential of bioactive compounds derived from ascidians for the treatment of the neurologic disorder-ASD.


Subject(s)
Autism Spectrum Disorder/drug therapy , Urochordata/chemistry , Animals , Humans
7.
Neurochem Res ; 44(11): 2684, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31628643

ABSTRACT

The original version of this article unfortunately contains an error in Fig. 2a (4th image for walnut). This has been corrected by publishing this erratum.

8.
Article in English | MEDLINE | ID: mdl-30654089

ABSTRACT

Dendritic spines are small, thin, specialized protrusions from neuronal dendrites, primarily localized in the excitatory synapses. Sophisticated imaging techniques revealed that dendritic spines are complex structures consisting of a dense network of cytoskeletal, transmembrane and scaffolding molecules, and numerous surface receptors. Molecular signaling pathways, mainly Rho and Ras family small GTPases pathways that converge on actin cytoskeleton, regulate the spine morphology and dynamics bi-directionally during synaptic activity. During synaptic plasticity the number and shapes of dendritic spines undergo radical reorganizations. Long-term potentiation (LTP) induction promote spine head enlargement and the formation and stabilization of new spines. Long-term depression (LTD) results in their shrinkage and retraction. Reports indicate increased spine density in the pyramidal neurons of autism and Fragile X syndrome patients and reduced density in the temporal gyrus loci of schizophrenic patients. Post-mortem reports of Alzheimer's brains showed reduced spine number in the hippocampus and cortex. This review highlights the spine morphogenesis process, the activity-dependent structural plasticity and mechanisms by which synaptic activity sculpts the dendritic spines, the structural and functional changes in spines during learning and memory using LTP and LTD processes. It also discusses on spine status in neurodegenerative diseases and the impact of nootropics and neuroprotective agents on the functional restoration of dendritic spines.


Subject(s)
Dendritic Spines/physiology , Animals , Dendritic Spines/drug effects , Humans , Nervous System Diseases/drug therapy , Nervous System Diseases/physiopathology , Neuronal Plasticity/physiology
9.
Neurotox Res ; 34(3): 597-612, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30006683

ABSTRACT

Many studies reported the neuroprotective effects of angiotensin II type 1 receptor (AT1R) antagonists in Parkinson's disease (PD). However, the role of AT1R blockade on astroglial, in turn, dopaminergic functions in chronic PD is still to be studied. In the present study, telmisartan (TEL; 3 and 10 mg/kg/day; p.o), was used to study the effects AT1R blockade on astrocytic and dopaminergic functions in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinsonism (250 mg/kg, i.p, in 10 equally divided doses at 3.5 days interval) in C57BL/6 J mice. TEL significantly downregulated glial fibrillary acidic protein (GFAP), inducible nitric oxide synthase (iNOS), TNFα and IL1ß expressions and nitric oxide (NO) content. Significant upregulation glial cell derived neurotrophic factor (GDNF) expression and increased glutathione (GSH) content reveal the ameliorating effects of TEL on astroglial functions. On the other hand, TEL upregulated tyrosine hydroxylase (TH), dopamine transporter (DAT), and vesicular monoamine transporter 2 (VMAT2) expressions. Finally, TEL improved dopamine and its turnover and restored locomotor performance. Present experiment reveals that TEL has the potential to alleviate astroglial functions, apart from restoring dopaminergic functions, at least in part. To conclude, TEL may be a better disease-modifying therapeutic regimen in the management of Parkinsonism, acting primarily via astroglial-dopaminergic functions.


Subject(s)
Astrocytes/drug effects , Dopamine/metabolism , Parkinsonian Disorders/drug therapy , Parkinsonian Disorders/pathology , Telmisartan/pharmacology , Telmisartan/therapeutic use , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Animals , Chronic Disease , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Disease Models, Animal , Gene Expression Regulation/drug effects , Glutathione/metabolism , Male , Mice , Mice, Inbred C57BL , Nerve Tissue Proteins/metabolism , Nitric Oxide/metabolism , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/physiopathology , Psychomotor Disorders/drug therapy , Psychomotor Disorders/etiology , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Walking
10.
Pharmacogn Mag ; 14(53): 9-16, 2018.
Article in English | MEDLINE | ID: mdl-29576695

ABSTRACT

BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder (NDD) associated with the loss of dopaminergic neurons in the substantia nigra and subsequently has an effect on motor function and coordination. The pathology of PD is multifactorial, in which neuroinflammation and oxidative damage are the two of the main protagonists. OBJECTIVES: The present study aims to assess the potential antioxidant and anti-inflammatory effects of demethoxycurcumin (DMC), a natural derivative of curcumin, against rotenone-induced PD in rats. MATERIALS AND METHODS: Rats were randomized and divided into six groups: control, rotenone (0.5 mg/kg/day, intraperitoneal in sunflower oil) treated for 7 days, rotenone and DMC (5, 10, and 20 mg/kg b.w) cotreated, and DMC (20 mg/kg b.w) alone treated groups. RESULTS: Based on the dopamine concentration and biochemical estimations, the effective dose of DMC was selected and the chronic study was performed. At the end of the experimental period, behavioral studies and protein expression patterns of inflammatory markers were analyzed. Rotenone treatment led to motor dysfunctions, neurochemical deficits, and oxidative stress and enhanced expressions of inflammatory markers, whereas oral administration of DMC attenuated all the above. CONCLUSION: Even though further research is needed to prove its efficacy in clinical trial, the results of our study showed that DMC may offer a promising and new therapeutic lead for the treatment of NDDs including PD. SUMMARY: Curcumin and their derivatives have been shown to be potent neuroprotective effectDemethoxycurcumin (DMC) amolerated the rotenone induced behavioural alterationsDMC abrogated the rotenone induced dopamine deficitsDMC attenuated the rotenone induced oxidative stressDMC diminished the rotenone mediated inflammation. Abbreviations used: COX-2: Cyclooxygenase-2; DA: Dopamine; DMC: Demethoxycurcumin; DMRT: Duncan's multiple range test; GSH: Reduced glutathione; GPx: Glutathione peroxidase; IL-1 ß: Interleukin-1 ß; IL-6: Interleukin-6; iNOS: Inducible nitric oxide synthase; PD: Parkinson's disease; SN: Substantia nigra; SOD: Superoxide dismutase; TBARS: Thiobarbituric acid reactive substances; TNF-α: Tumor necrosis factor-α.

11.
Neurotox Res ; 33(3): 656-670, 2018 04.
Article in English | MEDLINE | ID: mdl-29427283

ABSTRACT

The present study was designed to ascertain the role of naringenin (NGN), a citrus fruit flavanone, against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced α-synuclein (SYN) pathology and neuroinflammation in a mouse model. NGN was administered to C57BL/6J mice once a day for 5 consecutive days prior to the MPTP intoxication. On day 5, 40-50 min after the NGN or vehicle administration, MPTP was injected in two divided doses (2× 40 mg/kg, i.p. at 16 h apart). The animals were observed for motor functions 48 h after the first MPTP injection. The animals were then euthanized, the brains collected to analyze SYN pathology, cytokines, and oxidative stress levels in the substantia nigra region. The NGN significantly downregulated SYN and upregulated dopamine transporter (DAT) and tyrosine hydroxylase (TH) protein expressions. It also downregulated tumor necrosis factor-α (TNFα) and interleukin 1ß (IL1ß) mRNA expressions and improved superoxide dismutase levels. It also reduced glutathione levels when compared to vehicle-treated PD animals. The upregulation of TH corroborates to an increase in dopamine, DOPAC, and homovanillic acid turnover and motor functions with NGN treatment. To summarize, NGN, a dietary flavone, has the potential to counteract MPTP-induced dopaminergic degeneration by regulating SYN pathology, neuroinflammation, and oxidative stress. This warrants the investigation of NGN's potential effects in a genetic model of PD.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/pharmacology , Anti-Inflammatory Agents/therapeutic use , Encephalitis/etiology , Flavanones/therapeutic use , Gene Expression Regulation/drug effects , Parkinson Disease , alpha-Synuclein/metabolism , Animals , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Dopamine Plasma Membrane Transport Proteins/genetics , Dopamine Plasma Membrane Transport Proteins/metabolism , Glutathione/metabolism , Locomotion/drug effects , Male , Mice , Mice, Inbred C57BL , Muscle Strength/drug effects , Neurotransmitter Agents/metabolism , Nitric Oxide/metabolism , Oxidative Stress/drug effects , Parkinson Disease/complications , Parkinson Disease/drug therapy , Parkinson Disease/etiology , RNA, Messenger/metabolism , Tyrosine 3-Monooxygenase/genetics , Tyrosine 3-Monooxygenase/metabolism
12.
PLoS One ; 11(11): e0165955, 2016.
Article in English | MEDLINE | ID: mdl-27893738

ABSTRACT

Alzheimer's disease (AD) is the most common form of dementia that mainly affects the cognitive functions of the aged populations. Trigonella foenum-graecum (L.) (fenugreek), a traditionally well utilized medicinal plant ubiquitously used as one of the main food additive worldwide, is known to have numerous beneficial health effects. Fenugreek seed extract could be able to inhibit the activity of acetylcholinesterase (AChE), a key enzyme involved in the pathogenesis of AD, and further shown to have anti-parkinsonic effect. The present study was aimed to explore the neuroprotective effect of fenugreek seed powder (FSP) against aluminium chloride (AlCl3) induced experimental AD model. Administration of germinated FSP (2.5, 5 and 10% mixed with ground standard rat feed) protected AlCl3 induced memory and learning impairments, Al overload, AChE hyperactivity, amyloid ß (Aß) burden and apoptosis via activating Akt/GSK3ß pathway. Our present data could confirm the neuroprotective effect of fenugreek seeds. Further these results could lead a possible therapeutics for the management of neurodegenerative diseases including AD in future.


Subject(s)
Aluminum Compounds/toxicity , Apoptosis/drug effects , Chlorides/toxicity , Memory Disorders/drug therapy , Neuroprotective Agents/pharmacology , Plant Extracts/pharmacology , Acetylcholinesterase/metabolism , Aluminum Chloride , Amyloid beta-Peptides/metabolism , Animals , Glycogen Synthase Kinase 3 beta/metabolism , Learning/drug effects , Male , Memory Disorders/chemically induced , Plants, Medicinal/chemistry , Proto-Oncogene Proteins c-akt/metabolism , Rats, Wistar , Signal Transduction/drug effects , Trigonella , Weight Loss/drug effects
13.
Adv Neurobiol ; 12: 153-71, 2016.
Article in English | MEDLINE | ID: mdl-27651253

ABSTRACT

Alzheimer's disease (AD) is the most common neurodegenerative disease, characterized by notable memory loss, cognitive impairment, and personality disorders accompanied with structural abnormalities in the brain of aged population. Currently approved drugs for AD offer symptomatic relief without preventing the progression of the disease and having limited efficacy. Many experiments and clinical trials have shown that the traditional herbal medicine, which has multiple targets, could provide effective treatment of AD. Increasing evidence suggests that the plant derived polyphenols plays a key role in improving cognitive functions and preventing/delaying the onset of certain neurodegenerative diseases including AD. Although several biological effects based on experimental studies could be scientifically explained, the way to bring natural polyphenols into routine clinical application against neurodegeneration seems to be long, because of its low average daily intake, poor availability and few adverse effects. So the better knowledge about intestinal absorption, excretion, intestinal and hepatic metabolism, plasma kinetics, the nature of circulating metabolites, transport, cellular uptake, intracellular metabolism, and accumulation in tissues including brain will facilitate current scientific understanding and offer great hope for the prevention of AD.


Subject(s)
Alzheimer Disease/therapy , Phytotherapy , Polyphenols/therapeutic use , Humans
14.
Oncotarget ; 7(40): 64589-64604, 2016 Oct 04.
Article in English | MEDLINE | ID: mdl-27486879

ABSTRACT

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by extracellular plaques containing abnormal Amyloid Beta (Aß) aggregates, intracellular neurofibrillary tangles containing hyperphosphorylated tau protein, microglia-dominated neuroinflammation, and impairments in synaptic plasticity underlying cognitive deficits. Therapeutic strategies for the treatment of AD are currently limited. In this study, we investigated the effects of dietary supplementation of 4% pomegranate extract to a standard chow diet on neuroinflammation, and synaptic plasticity in APPsw/Tg2576 mice brain. Treatment with a custom mixed diet (pellets) containing 4% pomegranate for 15 months ameliorated the loss of synaptic structure proteins, namely PSD-95, Munc18-1, and SNAP25, synaptophysin, phosphorylation of Calcium/Calmodulin Dependent Protein Kinase IIα (p-CaMKIIα/ CaMKIIα), and phosphorylation of Cyclic AMP-Response Element Binding Protein (pCREB/CREB), inhibited neuroinflammatory activity, and enhanced autophagy, and activation of the phophoinositide-3-kinase-Akt-mammalian target of rapamycin signaling pathway. These neuroprotective effects were associated with reduced ß-site cleavage of Amyloid Precursor Protein in APPsw/Tg2576 mice. Therefore, long-term supplementation with pomegranates can attenuate AD pathology by reducing inflammation, and altering APP-dependent processes.


Subject(s)
Alzheimer Disease/diet therapy , Brain/immunology , Electrical Synapses/metabolism , Inflammation/diet therapy , Lythraceae , Plant Extracts/therapeutic use , Plaque, Amyloid/metabolism , Alzheimer Disease/metabolism , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Brain/pathology , Diet , Disease Models, Animal , Disks Large Homolog 4 Protein/metabolism , Female , Humans , Inflammation/metabolism , Mice , Mice, Transgenic , Munc18 Proteins/metabolism , Neuronal Plasticity/drug effects , Neuroprotective Agents , Oncogene Protein v-akt/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction/drug effects , Synaptosomal-Associated Protein 25/metabolism , TOR Serine-Threonine Kinases/metabolism
15.
PLoS One ; 11(1): e0146671, 2016.
Article in English | MEDLINE | ID: mdl-26765842

ABSTRACT

Parkinson's disease (PD) is regarded as a movement disorder mainly affecting the elderly population and occurs due to progressive loss of dopaminergic (DAergic) neurons in nigrostriatal pathway. Patients suffer from non-motor symptoms (NMS) such as depression, anxiety, fatigue and sleep disorders, which are not well focussed in PD research. Depression in PD is a predominant /complex symptom and its pathology lies exterior to the nigrostriatal system. The main aim of this study is to explore the causative or progressive effect of chronic mild stress (CMS), a paradigm developed as an animal model of depression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (25 mg/kg. body wt.) with probenecid (250 mg/kg, s.c.) (MPTP/p) induced mice model of PD. After ten i.p. injections (once in 3.5 days for 5 weeks) of MPTP/p or exposure to CMS for 4 weeks, the behavioural (motor and non-motor) impairments, levels and expressions of dopamine (DA), serotonin (5-HT), DAergic markers such as tyrosine hydroxylase (TH), dopamine transporter (DAT), vesicular monoamine transporters-2 (VMAT 2) and α-synuclein in nigrostriatal (striatum (ST) and substantia nigra (SN)) and extra-nigrostriatal (hippocampus, cortex and cerebellum) tissues were analysed. Significantly decreased DA and 5-HT levels, TH, DAT and VMAT 2 expressions and increased motor deficits, anhedonia-like behaviour and α-synuclein expression were found in MPTP/p treated mice. Pre and/or post exposure of CMS to MPTP/p mice further enhanced the MPTP/p induced DA and 5-HT depletion, behaviour abnormalities and protein expressions. Our results could strongly confirm that the exposure of stress after MPTP/p injections worsens the symptoms and neurochemicals status of PD.


Subject(s)
Brain/metabolism , MPTP Poisoning/metabolism , Stress, Psychological/metabolism , Animals , Behavior, Animal , Brain/physiology , Dopamine/metabolism , Locomotion , MPTP Poisoning/complications , MPTP Poisoning/physiopathology , Male , Mice , Mice, Inbred C57BL , Organ Specificity , Probenecid/toxicity , Serotonin/metabolism , Stress, Psychological/complications , Stress, Psychological/physiopathology , Tyrosine 3-Monooxygenase/metabolism , Vesicular Monoamine Transport Proteins/metabolism , alpha-Synuclein/metabolism
16.
Nutr Neurosci ; 19(6): 237-46, 2016 Jul.
Article in English | MEDLINE | ID: mdl-25730317

ABSTRACT

OBJECTIVE: Mitochondrial dysfunction and oxidative stress-mediated apoptosis plays an important role in various neurodegenerative diseases including Huntington's disease, Parkinson's disease (PD) and Alzheimer's disease (AD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the most widely used neurotoxin mimics the symptoms of PD by inhibiting mitochondrial complex I that stimulates excessive intracellular reactive oxygen species (ROS) and finally leads to mitochondrial-dependent apoptosis. Lutein, a carotenoid of xanthophyll family, is found abundantly in leafy green vegetables such as spinach, kale and in egg yolk, animal fat and human eye retinal macula. Increasing evidence indicates that lutein has offers benefits against neuronal damages during diabetic retinopathy, ischemia and AD by virtue of its mitochondrial protective, antioxidant and anti-apoptotic properties. METHODS: Male C57BL/6 mice (23-26 g) were randomized and grouped in to Control, MPTP, and Lutein treated groups. RESULTS: Lutein significantly reversed the loss of nigral dopaminergic neurons by increasing the striatal dopamine level in mice. Moreover, lutein-ameliorated MPTP induced mitochondrial dysfunction, oxidative stress and motor abnormalities. In addition, lutein repressed the MPTP-induced neuronal damage/apoptosis by inhibiting the activation of pro-apoptotic markers (Bax, caspases-3, 8 and 9) and enhancing anti-apoptotic marker (Bcl-2) expressions. DISCUSSION: Our current results revealed that lutein possessed protection on dopaminergic neurons by enhancing antioxidant defense and diminishing mitochondrial dysfunction and apoptotic death, suggesting the potential benefits of lutein for PD treatment.


Subject(s)
Apoptosis , Dietary Supplements , Dopaminergic Neurons/metabolism , Lutein/therapeutic use , Mitochondria/metabolism , Neuroprotective Agents/therapeutic use , Parkinson Disease/prevention & control , Animals , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/adverse effects , Antiparkinson Agents/therapeutic use , Apoptosis/drug effects , Apoptosis Regulatory Proteins/agonists , Apoptosis Regulatory Proteins/antagonists & inhibitors , Apoptosis Regulatory Proteins/metabolism , Behavior, Animal/drug effects , Biomarkers/metabolism , Dietary Supplements/adverse effects , Dopamine/chemistry , Dopamine/metabolism , Dopaminergic Neurons/drug effects , Lutein/administration & dosage , Lutein/adverse effects , MPTP Poisoning/etiology , MPTP Poisoning/metabolism , MPTP Poisoning/physiopathology , Male , Mice, Inbred C57BL , Mitochondria/drug effects , Motor Activity/drug effects , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/metabolism , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/adverse effects , Oxidative Stress/drug effects , Parkinson Disease/etiology , Parkinson Disease/metabolism , Random Allocation , Substantia Nigra/drug effects , Substantia Nigra/metabolism
17.
Neurosci Lett ; 599: 12-9, 2015 Jul 10.
Article in English | MEDLINE | ID: mdl-25980996

ABSTRACT

Parkinson's disease (PD) is the second most common neurodegenerative disorder that mainly affects the movement of the aged populations. Lycopene is a carotenoid with unique pharmacological properties and its efficacy on experimental Hunginton's disease and brain ischemia has shown intense neuroprotective effects. The present study was aimed to explore the neuroprotective effect of lycopene against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD mice. Administration of lycopene (5, 10 and 20 mg/kg/day orally) protected MPTP induced depletion of striatal dopamine (DA) and its metabolites in a dose dependent manner. It also attenuated MPTP-induced oxidative stress and motor abnormalities seen in PD mice. Our western blot studies showed that treatment with lycopene reversed MPTP induced apoptosis may be due to its antioxidant and antiapoptotic properties. As to conclude, lycopene reverses neurochemical deficts, oxidative stress, apoptosis and physiological abnormalities in PD mice and offer promise strategy in the treatment of this neurodegenerative disease.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Carotenoids/pharmacology , Neuroprotective Agents/pharmacology , Parkinson Disease/drug therapy , Animals , Apoptosis/drug effects , Carotenoids/therapeutic use , Caspase 3/metabolism , Caspase 8/metabolism , Caspase 9/metabolism , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Cytochromes c/metabolism , Dopamine/metabolism , Hand Strength , Lycopene , Male , Mice, Inbred C57BL , Neuroprotective Agents/therapeutic use , Oxidative Stress/drug effects , Parkinson Disease/etiology , Parkinson Disease/physiopathology , Proto-Oncogene Proteins c-bcl-2/metabolism , Substantia Nigra/drug effects , Substantia Nigra/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...